ABOUT LINK ALTERNATIF MBL77

Other than ibrutinib, people with M-CLL, devoid of TP53 aberrations and in shape adequate to tolerate FCR therapy, should be excellent candidates with the latter, with the profit currently being that this procedure can be concluded in 6 months when ibrutinib should be taken indefinitely. This option could be specifically important for non-compliant